LivaNova (LIVN) Q3 2026 Earnings Call Transcript
LivaNova (LIVN) reported Q3 2026 revenue growth of 11% in cardiopulmonary and 11% in epilepsy, raising full-year guidance to 9-10%. The company announced new CPT codes for its OSA technology, expected in 2028, and launched a new oxygenator production line. Epilepsy revenue grew due to volume and pricing, with strong clinical evidence supporting VNS therapy.
How this was made
The 30-second read
Why it matters
The guidance lift reflects stronger demand and operational improvements, likely prompting a positive market reaction.
Market read
First‑time disclosure of higher 2026 growth guidance makes the call highly relevant for traders targeting healthcare equipment stocks.
What to watch
Execution risk on the new oxygenator line and reimbursement uncertainties for OSA codes could temper upside.
Background
LivaNova's Q3 2026 earnings call covered revenue growth, new manufacturing capacity, and upcoming CPT code approvals for its OSA therapy.
Ticker impact
LivaNova raised its full-year 2026 revenue growth outlook to 9-10% from 8-9% and increased cardiopulmonary growth guidance to 10.5-11.5% from 9.5-10.5%, providing fresh guidance in its Q3 earnings call.
upward pressure as investors price in higher revenue growth expectations
The guidance lift is the first public disclosure and exceeds prior expectations, which typically drives buying interest.
Market effects
Higher growth outlook may boost the broader medical device sector, especially cardiopulmonary and neurostimulation segments.
Positive for U.S. and European markets where LivaNova has significant sales exposure.
Adds optimism to global healthcare equipment outlook, potentially influencing related ETFs.
Counterpoint
If the guidance upgrade is already priced in, the stock could face a short‑term pull‑back.
Key entities
- companyLivaNova
Medical device maker focused on cardiopulmonary and neurostimulation products.
- partnerThermo Fisher
Component supplier supporting LivaNova's oxygenator expansion.
